Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;1(2):69-77.
doi: 10.1177/1758834009343454.

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER

Tanya B Dorff  1 , Cathy M Tangen, E David Crawford, Daniel P Petrylak, Celestia S Higano, Derek Raghavan, David I Quinn, Nicholas J Vogelzang, Ian M Thompson, Maha H A Hussain
Affiliations

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER

Tanya B Dorff et al. Ther Adv Med Oncol. 2009.

Abstract

The major goals of the SWOG-GU committee in the area of advanced prostate cancer are to improve the survival and quality of life of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Banerjee S., Hussain M., Wang Z., Saliganan A., Che M., Bonfil D., et al. (2007) In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 67: 3818–26 - PubMed
    1. Beer T.M., Goldman B., Synold T.W., Ryan C.W., Vasist L.S., VanVeldheusin Jr P.J., et al. (2008) Southwest oncology group phase II study of ispenesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 6: 103–9 - PubMed
    1. Beer T.M., Tangen C.M., Bland L.B., Hussain M., Goldman B.H., deLoughery T.G., et al. (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. Cancer 107: 489–96 - PubMed
    1. Berruti A., Fara E., Tucci M., Tarabuzzi R., Mosca A., Terrone C., et al. (2005) Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Urol Oncol 23: 1–7 - PubMed
    1. Berry D.L., Moinpour C.M., Jiang C.S., Ankerst D.P., Petrylak D.P., Vinson L.V., et al. (2008) Quality of life and pain in advanced stage prostate cancer: results of a southwest oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24: 2828–35 - PubMed

LinkOut - more resources